Previous 10 | Next 10 |
2023-09-08 08:45:53 ET Palm Beach, FL – September 8, 2023 – FinancialNewsMedia.com News Commentary – The Global Dry Eye Syndrome market has been growing substantially in the past years and is expected to continue through 2030. Dry Eye Syndrome (DES) or Dry E...
2023-09-08 08:27:09 ET Aziyo Biologics ( ELUT ) +19% . Verb Technology Company ( VERB ) +21% . Plus Therapeutics ( PSTV ) +15% Signs CNSid Licensing Agreement with Plus Therapeutics. Bullfrog AI ( BFRG ) +16% Announces Investor Webinar with CEO an...
Full enrollment achieved on September 6 th with a total of 240 patients enrolled in study Top-line data planned for release in December 2023 Phase 2 trial is designed as a potential registration trial, with pre-specified primary efficacy endpoints covering both a sign ...
2023-08-31 12:41:47 ET Gainers: Acer Therapeutics ( ACER ) +133% . Prime Number Acquisition I Corp. ( NCNC ) +41% . Minim ( MINM ) +29% . Canopy Growth Corporation ( CGC ) +26% . Upland Software ( UPLD ) +23% . Hydrofarm Hold...
2023-08-31 10:00:40 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) Tech Ruled The First Half Of 2023, The Industry You Need To Watch In The Second Half XLV Vs. VHT: A Head-To-Head Healthcare ETF C...
2023-08-31 08:17:07 ET Dollar General DG -16% after Q2 release . OKYO Pharma ( OKYO ) -14% . Top KingWin ( TCJH ) -10% . ReTo Eco-Solutions ( RETO ) -11% . Beneficient ( BENF ) -10% . Digital Brands Group ( DBGI ) -9% . ...
2023-08-30 13:16:02 ET Gainers: NanoVibronix ( NAOV ) +127% . iCoreConnect ( ICCT ) +49% . Aravive ( ARAV ) +35% . AEON Biopharma ( AEON ) +33% . Alarum Technologies ( ALAR ) +25% . Greenland Technologies Holding Corporation ...
Full enrollment anticipated by first week of September OKYO on schedule to release top-line data before end of 2023 Phase 2 trial is designed as potential registration trial with pre-specified primary efficacy endpoints covering both a sign and symptom of DED LONDON and ...
2023-08-29 10:25:57 ET Are you trading penny stocks this week? Chances are that if you’re reading this article, you have some intention of finding more info on cheap stocks. Thanks to the heightened level of volatility in the stock market today, traders, in particular, have turne...
2023-08-29 07:59:26 ET More on OKYO Pharma OKYO Pharma rebounds on withdrawal of equity offering Seeking Alpha’s Quant Rating on OKYO Pharma Earnings data for OKYO Pharma For further details see: OKYO Pharma regains Nasdaq compliance
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...